Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $47.63 USD
Change Today -0.17 / -0.36%
Volume 1.8M
ZTS On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

zoetis inc (ZTS) Snapshot

Open
$47.71
Previous Close
$47.80
Day High
$47.84
Day Low
$47.50
52 Week High
04/24/15 - $47.99
52 Week Low
05/28/14 - $30.43
Market Cap
23.8B
Average Volume 10 Days
2.7M
EPS TTM
$1.45
Shares Outstanding
500.0M
EX-Date
04/7/15
P/E TM
32.9x
Dividend
$0.33
Dividend Yield
0.65%
Current Stock Chart for ZOETIS INC (ZTS)

zoetis inc (ZTS) Details

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. The company operates through four segments: the United States; Europe/Africa/Middle East; Canada/Latin America; and Asia/Pacific. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines that are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia and treating pain and serious illnesses, such as diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories, such as nutritionals and agribusiness, as well as products and services in complementary areas, including diagnostics, genetics, biodevices, and services. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

10,000 Employees
Last Reported Date: 02/27/15
Founded in 1952

zoetis inc (ZTS) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $207.6K
Executive Vice President and President of U.S...
Total Annual Compensation: $620.4K
Executive Vice President and President of Int...
Total Annual Compensation: $451.4K
President of Research & Development and Execu...
Total Annual Compensation: $451.4K
Compensation as of Fiscal Year 2014.

zoetis inc (ZTS) Key Developments

Zoetis to Dismiss at Least 20% of its Workers

Zoetis planned to dismiss at least 20% of its workers, shut 10 plants and drop some of its product lines as part of plans to cut $300 million in costs.

Zoetis Inc. Announces Executive Changes

Zoetis Inc. announced a comprehensive operational efficiency initiative designed to reduce complexity in its global operations and optimize its resource allocation and efficiency. In connection with this initiative, effective May 5, 2015, Clinton A. Lewis, Jr. will resign from his position as Executive Vice President and President, U.S. Operations and assume the role of Executive Vice President and President, International Operations, and Kristin C. Peck will resign from her position as Executive Vice President and Group President and assume the role of Executive Vice President and President, U.S. Operations.

Zoetis Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter of 2015; Revises Earnings Guidance for the Year 2015; Provides Earnings Guidance for the Year 2016 and 2017

Zoetis Inc. announced unaudited consolidated earnings results for the first quarter of 2015. For the quarter, the company reported revenue of $1.1 billion against $1,097 million a year ago, revenue reflected an operational increase of 6%, excluding the impact of foreign currency. Net income attributable to the company was $165 million, or $0.33 per diluted share against $155 million or $0.31 per diluted share a year ago. Adjusted net income was $207 million, or $0.41 per diluted share against $191 million or $0.38 per diluted share a year ago. On an operational basis, adjusted net income increased 14%, with foreign currency having a negative impact of 6% points. Income before provision for taxes on income was $230 million compared to $227 million a year ago. The company revised earnings guidance for the year 2015. For the year 2015, the company expects revenue of in between $4.675 billion to $4.775 billion compared to previous guidance of in between $4,800 million to $4,900 million. The company expects diluted EPS of in between $0.79 to $1.02 per share compared to previous guidance of in between $1.32 to $1.39. The company expects adjusted diluted EPS of in between $1.61 to $1.68 per share compared to previous guidance of in between $1.61 to $1.68. The company expects adjusted net income of in between $810 million to $845 million compared to previous guidance of in between $810 million to $845 million. The company expects net income attributable to the company of between $400 million to $515 million. The company expects a slightly higher effective tax rate for the remainder of the year of 2015 higher than the 27% that the company had in the fourth quarter of 2015 the operating expense benefits that the company is seeking will begin to be most evident in fourth quarter of 2014, and the company’s guidance assumes a constant diluted share count of approximately 502 million shares outstanding. The company expects effective tax rate on adjusted income of approximately 29%. The company provided earnings guidance for the year 2016 and 2017. For the year 2016, the company expects revenue of in between $4,650 million to $4,800 million; adjusted diluted EPS of in between $1.81 to $1.93, adjusted net income of in between $910 million to $970 million, reported diluted EPS of in between $1.45 to $1.65 and net income attributable to the company of in between $730 million to $830 million. The company expects adjusted EBIT margin of approximately 31%. The company expects effective tax rate on adjusted income of approximately 30%. For the year 2017, the company expected revenue of $4.850 billion to $5.050 billion, reported diluted EPS of between $1.98 to $2.16 per share and adjusted diluted EPS of $2.18 to $2.32. The company expected adjusted EBIT margin of approximately 34%. The company expected adjusted net income of in between $1,095 million to $1,165 million and net income attributable to company of in between $995 million to $1,085 million. The company expects effective tax rate on adjusted income of approximately 29%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZTS:US $47.63 USD -0.17

ZTS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abaxis Inc $52.69 USD -0.36
IDEXX Laboratories Inc $138.72 USD +0.69
Phibro Animal Health Corp $35.78 USD +0.33
Vetoquinol SA €35.80 EUR -0.06
Virbac SA €232.00 EUR -0.85
View Industry Companies
 

Industry Analysis

ZTS

Industry Average

Valuation ZTS Industry Range
Price/Earnings 40.4x
Price/Sales 5.0x
Price/Book 18.6x
Price/Cash Flow 36.5x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOETIS INC, please visit www.zoetis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.